On the stock market since 1993, it operates in the world of health and science. It has 713 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
The biggest line carries real weight, but it doesn’t decide everything on its own.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 16 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $252K against $118.4M in annual sales. And on top of that, sales fell from the year before.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 42/100.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, NSYS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: NSYS is a small company that closed last year at a loss. The road back to profit runs through spending discipline.